SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the adoption of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of Sept. 8, 2026, a 79% increase from 7,885 at the end of 2025. The installed base of systems grew 42% to 238 units from 168 during the same period. These figures underscore the company's expanding global reach and the increasing acceptance of its cost-effective robotic surgery platform.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the system, which has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the system's versatility and its potential to address unmet needs in diverse healthcare markets.
SS Innovations also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such achievements demonstrate the platform's reliability and efficiency, which are critical for broader adoption.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are pivotal for the company's expansion into major markets, potentially unlocking significant revenue opportunities and enhancing its competitive position against established players.
The global surgical robotics market is projected to grow substantially, driven by the demand for minimally invasive procedures and technological advancements. SS Innovations aims to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the SSi Mantra system and the SSi Mudra suite of surgical instruments, which support a variety of procedures, including cardiac surgery. As an American company headquartered in India, SS Innovations is strategically positioned to leverage cost advantages while targeting both emerging and developed markets.
Investors and industry observers will be watching the company's progress toward FDA clearance and CE marking, as these approvals could serve as catalysts for accelerated growth. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For a full report on the company's recent milestones, visit https://ibn.fm/DJILj.
The strong procedure growth and expanding installed base reflect rising confidence in SS Innovations' technology. If the company secures regulatory approvals as anticipated, it could significantly disrupt the surgical robotics landscape by offering a more affordable alternative to existing systems. This potential for market penetration makes SS Innovations a company to watch in the coming years.
